東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Polymeric nanoparticles for the intr...

Zubris, Kimberly Ann Veronica.

FindBook

Google Book

Amazon

博客來

Polymeric nanoparticles for the intracellular delivery of paclitaxel in lung and breast cancer.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Polymeric nanoparticles for the intracellular delivery of paclitaxel in lung and breast cancer./
作者:	Zubris, Kimberly Ann Veronica.
面頁冊數:	202 p.
附註:	Source: Dissertation Abstracts International, Volume: 72-09, Section: B, page: .
Contained By:	Dissertation Abstracts International72-09B.
標題:	Health Sciences, Pharmacology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3463295
ISBN:	9781124755373

Polymeric nanoparticles for the intracellular delivery of paclitaxel in lung and breast cancer.
Zubris, Kimberly Ann Veronica.

Polymeric nanoparticles for the intracellular delivery of paclitaxel in lung and breast cancer. - 202 p.

Source: Dissertation Abstracts International, Volume: 72-09, Section: B, page: .

Thesis (Ph.D.)--Boston University, 2011.

Nanoparticles are useful for addressing many of the difficulties encountered when administering therapeutic compounds. Nanoparticles are able to increase the solubility of hydrophobic drugs, improve pharmacokinetics through sustained release, alter biodistribution, protect sensitive drugs from low pH environments or enzymatic alteration, and, in some cases, provide targeting of the drug to the desired tissues. The use of functional nanocarriers can also provide controlled intracellular delivery of a drug. To this end, we have developed functional pH-responsive expansile nanoparticles for the intracellular delivery of paclitaxel. The pH-responsiveness of these nanoparticles occurs due to a hydrophobic to hydrophilic transition of the polymer occurring under mildly acidic conditions.

ISBN: 9781124755373Subjects--Topical Terms:

1017717
Health Sciences, Pharmacology.

Polymeric nanoparticles for the intracellular delivery of paclitaxel in lung and breast cancer.
LDR:03431nam 2200325 4500 001 1403230
005 20111111141840.5
008 130515s2011 ||||||||||||||||| ||eng d
020 $a 9781124755373
035 $a (UMI)AAI3463295
035 $a AAI3463295
040 $a UMI $c UMI
100 1 $a Zubris, Kimberly Ann Veronica. $3 1682482
245 1 0 $a Polymeric nanoparticles for the intracellular delivery of paclitaxel in lung and breast cancer.
300 $a 202 p.
500 $a Source: Dissertation Abstracts International, Volume: 72-09, Section: B, page: .
500 $a Adviser: Mark W. Grinstaff.
502 $a Thesis (Ph.D.)--Boston University, 2011.
520 $a Nanoparticles are useful for addressing many of the difficulties encountered when administering therapeutic compounds. Nanoparticles are able to increase the solubility of hydrophobic drugs, improve pharmacokinetics through sustained release, alter biodistribution, protect sensitive drugs from low pH environments or enzymatic alteration, and, in some cases, provide targeting of the drug to the desired tissues. The use of functional nanocarriers can also provide controlled intracellular delivery of a drug. To this end, we have developed functional pH-responsive expansile nanoparticles for the intracellular delivery of paclitaxel. The pH-responsiveness of these nanoparticles occurs due to a hydrophobic to hydrophilic transition of the polymer occurring under mildly acidic conditions.
520 $a These polymeric nanoparticles were systematically evaluated for the delivery of paclitaxel in vitro and in vivo to improve local therapy for lung and breast cancers. Nanoparticles were synthesized using a miniemulsion polymerization process and were subsequently characterized and found to swell when exposed to acidic environments. Paclitaxel was successfully encapsulated within the nanoparticles, and the particles exhibited drug release at pH 5 but not at pH 7.4. In addition, the uptake of nanoparticles was observed using flow cytometry, and the anticancer efficacy of the paclitaxel-loaded nanoparticles was measured using cancer cell lines in vitro. The potency of the paclitaxel-loaded nanoparticles was close to that of free drug, demonstrating that the drug was effectively delivered by the particles and that the particles could act as an intracellular drug depot.
520 $a Following in vitro characterization, murine in vivo studies demonstrated the ability of the paclitaxel-loaded responsive nanoparticles to delay recurrence of lung cancer and to prevent establishment of breast cancer in the mammary fat pads with higher efficacy than paclitaxel alone. In addition, the ability of nanoparticles to migrate up to 40 cm through lymphatic channels to local lymph nodes was demonstrated using near infrared imaging in a large animal model. Continued investigation of functional nanoparticles, like the system described here for lung and breast cancer, will facilitate the development of new materials that meet the varied and demanding needs in chemotherapy, and may afford new treatment options for the local and metastatic control of many forms of cancer.
590 $a School code: 0017.
650 4 $a Health Sciences, Pharmacology. $3 1017717
650 4 $a Engineering, Biomedical. $3 1017684
650 4 $a Nanotechnology. $3 526235
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0419
690 $a 0541
690 $a 0652
690 $a 0992
710 2 $a Boston University. $3 1017454
773 0 $t Dissertation Abstracts International $g 72-09B.
790 1 0 $a Grinstaff, Mark W., $e advisor
790 $a 0017
791 $a Ph.D.
792 $a 2011
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3463295